Patents by Inventor Zhongyong Wei

Zhongyong Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycosidase inhibitors and uses thereof
    Patent number: 9938299
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Kun Liu, Ernest J. McEachern, Ramesh Kaul, Zhongyong Wei, Yaode Wang, Jiang Chang
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9718854
    Abstract: The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: August 1, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • Permeable glycosidase inhibitors and uses thereof
    Patent number: 9611275
    Abstract: The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 4, 2017
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Wenping Li, Eric Hostetler, Kun Liu, Ernest J. McEachern, Yuanxi Zhou, Zhongyong Wei, Changwei Mu, Yaode Wang, Jiang Chang
  • Pyrazole carboxamides as Janus kinase inhibitors
    Patent number: 9394282
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: July 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Brubaker, Joshua Close, Tony Siu, Graham Frank Smith, Luis E. Torres, Hyun Chong Woo, Jonathan R. Young, Zhongyong Wei, Feng Shi
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20160194337
    Abstract: A locking arrangement secures together first and second panels. The arrangement includes locking tabs (54, 56, 58) projecting from an end edge (64) of the first panel (12) and locking slits (50a, 50b, 50c) in the second panel (28). Each locking slit is provided for receiving a respective one of the locking tabs. The locking tabs and the locking slits are engageable by relative sliding movement with each other. At least one of the locking tabs and locking slits is configured to secure the first and second panels in a first overlapping position while at least another one of the locking tabs and locking slits is configured to secure the first and second panels in a second overlapping position.
    Type: Application
    Filed: December 8, 2013
    Publication date: July 7, 2016
    Inventors: HAROLD G. SELNICK, KUN LIU, ERNEST J. MCEACHERN, RAMESH KAUL, ZHONGYONG WEI, YAODE WANG, JIANG CHANG
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20160096858
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Changwei MU, Harold G. SELNICK, David J. VOCADLO, Yaode WANG, Zhongyong WEI, Yuanxi ZHOU, Yongbao ZHU
  • PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20150152127
    Abstract: The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.
    Type: Application
    Filed: May 3, 2013
    Publication date: June 4, 2015
    Inventors: Harold G. Selnick, Wenping Li, Eric Hostetler, Kun Liu, Ernest J. McEachern, Yuanxi Zhou, Zhongyong Wei, Changwei Mu, Yaode Wang, Jiang Chang
  • Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
    Patent number: 8962608
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: February 24, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Brubaker, Christopher Dinsmore, Dawn Marie Hoffman, Joon Jung, Duan Liu, Scott Peterson, Tony Siu, Luis E. Torres, Hongjun Zhang, Zhongyong Wei, Feng Shi
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 8933040
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: January 13, 2015
    Inventors: Craig A. Coburn, Kun Liu, Ernest J. McEacher, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 8901087
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiang Chang, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, Feng Shi, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS
    Publication number: 20140243309
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 28, 2014
    Inventors: Jason Brubaker, Christopher Dinsmore, Dawn Marie Hoffman, Joon Jung, Duan Liu, Scott Peterson, Tony Siu, Luis E. Torres, Hongjun Zhang, Zhongyong Wei, Feng Shi
  • PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS
    Publication number: 20140235641
    Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 21, 2014
    Inventors: Jason Brubaker, Joshua Close, Tony Siu, Graham Frank Smith, Luis E. Torres, Hyun Chong Woo, Jonathan R. Young, Zhongyong Wei, Feng Shi
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140213584
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: November 8, 2011
    Publication date: July 31, 2014
    Applicants: Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.
    Inventors: Craig A. Coburn, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140088028
    Abstract: The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Application
    Filed: March 20, 2012
    Publication date: March 27, 2014
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140018309
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 21, 2011
    Publication date: January 16, 2014
    Applicants: MERCK SHARP & DOHME CORP., ALECTOS THERAPEUTICS, INC.
    Inventors: Ramesh Kaul, Ernest J. Mceachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140005191
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: November 9, 2011
    Publication date: January 2, 2014
    Applicants: Merck Sharp & Dohme Corp., Alectos Therapeutics Inc.
    Inventors: Craig A. Coburn, Kun Liu, Ernest J. McEacher, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20130296301
    Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: November 8, 2011
    Publication date: November 7, 2013
    Inventors: Jiang Chang, Kun Liu, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, Feng Shi, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Novel Compounds with Analgesic Effect
    Publication number: 20080176903
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Application
    Filed: December 5, 2007
    Publication date: July 24, 2008
    Applicant: ASTRAZENECA CANADA INC.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
    Patent number: 7384955
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof Formula (I) wherein Ar, R1, R2, R3, Ra, Rb and X are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: June 10, 2008
    Assignee: AstraZeneca AB
    Inventors: Zhongyong Wei, Regis Dolaine, Christopher Walpole, Hua Yang